Brian F Thomas

List of Publications by Year
in descending order

75 papers	3,504 citations	159358 30 h-index	143772 57 g-index
77 all docs	77 docs citations	77 times ranked	3358 citing authors

#	Article	IF	Citations
1	Bisphenol A Exposure Causes Meiotic Aneuploidy in the Female Mouse. Current Biology, 2003, 13, 546-553.	1.8	575
2	Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacology Biochemistry and Behavior, 1991, 40, 471-478.	1.3	384
3	Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women,,. American Journal of Clinical Nutrition, 2002, 76, 1126-1137.	2.2	162
4	Potent rewarding and reinforcing effects of the synthetic cathinone 3,4â€methylenedioxypyrovalerone (<scp>MDPV</scp>). Addiction Biology, 2014, 19, 165-174.	1.4	156
5	AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Î”⁹-Tetrahydrocannabinolâ€“Like Effects in Mice. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 328-339.	1.3	110
6	Structureâ€'Activity Analysis of Anandamide Analogs:Â Relationship to a Cannabinoid Pharmacophoreâ€. Journal of Medicinal Chemistry, 1996, 39, 471-479.	2.9	101
7	Synthesis and Structureâ€'Activity Relationships of Amide and Hydrazide Analogues of the Cannabinoid CB1 Receptor Antagonist N-(Piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716). Journal of Medicinal Chemistry, 2002, 45, 2708-2719.	2.9	94
8	Cannabinoids in disguise: Î”9-Tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology, 2013, 75, 145-154.	2.0	94
9	Analysis of Synthetic Cannabinoids Using High-Resolution Mass Spectrometry and Mass Defect Filtering: Implications for Nontargeted Screening of Designer Drugs. Analytical Chemistry, 2012, 84, 5574-5581.	3.2	91
10	Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor. Medicinal Research Reviews, 2017, 37, 441-474.	5.0	76
11	Quantitative analysis of the principle soy isoflavones genistein, daidzein and glycitein, and their primary conjugated metabolites in human plasma and urine using reversed-phase high-performance liquid chromatography with ultraviolet detection. Biomedical Applications, 2001, 760, 191-205.	1.7	70
12	Dose-Response Effects of Spectrum Research Cigarettes. Nicotine and Tobacco Research, 2013, 15, 1113-1121.	1.4	69
13	Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 437-446.	1.3	69
14	Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development. Current Topics in Medicinal Chemistry, 2019, 19, 1418-1435.	1.0	69
15	Synthesis and Pharmacological Comparison of Dimethylheptyl and Pentyl Analogs of Anandamide. Journal of Medicinal Chemistry, 1997, 40, 3626-3634.	2.9	63
16	Synthesis and Biological Evaluation of Bivalent Ligands for the Cannabinoid 1 Receptor. Journal of Medicinal Chemistry, 2010, 53, 7048-7060.	2.9	62
17	The Bioactive Conformation of Aminoalkylindoles at the Cannabinoid CB1 and CB2 Receptors:Â Insights Gained from (E)- and (Z)-Naphthylidene Indenes. Journal of Medicinal Chemistry, 1998, 41, 5177-5187.	2.9	60
18	Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain. Journal of Medicinal Chemistry, 2016, 59, 7525-7543.	2.9	53

#	Article	IF	Citations
19	Relationship between the biodisposition of [3H]soman and its pharmacological effects in mice. Toxicology and Applied Pharmacology, 1985, 80, 409-420.	1.3	49
20	Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of inÂvivo assays in mice. Neuropharmacology, 2016, 110, 143-153.	2.0	49
21	Hijacking of Basic Research: The Case of Synthetic Cannabinoids. , 2011, 2011, .		45
22	Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 162-171.	1.3	41
23	Diarylureas as Allosteric Modulators of the Cannabinoid CB1 Receptor: Structureâ€“Activity Relationship Studies on 1-(4-Chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). Journal of Medicinal Chemistry, 2014, 57, 7758-7769.	2.9	40
24	Structureâ€“activity relationships for 1â€²,1â€²-dimethylalkyl-Î” 8 -tetrahydrocannabinols. Bioorganic and Medicinal Chemistry, 2003, 11, 1397-1410.	1.4	38
25	Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents. Psychopharmacology, 2010, 210, 275-284.	1.5	37
26	Substituted Tetrahydroisoquinolines as Selective Antagonists for the Orexin 1 Receptor. Journal of Medicinal Chemistry, 2013, 56, 6901-6916.	2.9	36
27	In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA. Forensic Toxicology, 2017, 35, 333-347.	1.4	35
28	Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders. International Review of Psychiatry, 2009, 21, 134-142.	1.4	33
29	Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice. Substance Abuse: Research and Treatment, 2017, 11, 117822181770173.	0.5	33
30	Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 414-422.	1.3	33
31	Use of SPME-HS-GC-MS for the Analysis of Herbal Products Containing Synthetic Cannabinoids. Journal of Analytical Toxicology, 2012, 36, 293-302.	1.7	32
32	Structureâ€“activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators. Bioorganic and Medicinal Chemistry, 2015, 23, 2195-2203.	1.4	31
33	QSAR Analysis of Î”8-THC Analogues:Â Relationship of Side-Chain Conformation to Cannabinoid Receptor Affinity and Pharmacological Potency. Journal of Medicinal Chemistry, 2000, 43, 59-70.	2.9	30
34	Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists. Neuropharmacology, 2018, 134, 73-81.	2.0	29
35	Combination Chemistry: Structureâ€“Activity Relationships of Novel Psychoactive Cannabinoids. Current Topics in Behavioral Neurosciences, 2016, 32, 231-248.	0.8	28
36	Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. Forensic Toxicology, 2019, 37, 17-26.	1.4	28

#	Article	IF	Citations
37	Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. Bioorganic and Medicinal Chemistry, 2005, 13, 5463-5474.	1.4	27
38	Toward the Development of Bivalent Ligand Probes of Cannabinoid CB1 and Orexin OX1 Receptor Heterodimers. ACS Medicinal Chemistry Letters, 2014, 5, 634-638.	1.3	25
39	Synthesis and in vivo studies of a selective ligand for the dopamine transporter: 3Î²-(4-[125I]iodophenyl) tropan-2Î²-carboxylic acid isopropyl ester ([125I]RTM-21). Nuclear Medicine and Biology, 1996, 23, 277-284.	0.3	24
40	The great divide: Separation between inÂvitro and inÂvivo effects of PSNCBAM-based CB 1 receptor allosteric modulators. Neuropharmacology, 2017, 125, 365-375.	2.0	23
41	Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution. Journal of Medicinal Chemistry, 2017, 60, 7410-7424.	2.9	21
42	Identification of Eight Synthetic Cannabinoids, Including 5Fâ€AKB48 in Seized Herbal Products Using DARTâ€TOFâ€MS and LCâ€QTOFâ€MS as Nontargeted Screening Methods. Journal of Forensic Sciences, 2017, 62, 1151-1158.	0.9	20
43	Determination of ibogaine in plasma by gas chromatography-chemical ionization mass spectrometry. Journal of Chromatography A, 1996, 723, 101-109.	1.8	19
44	The Importance of Hydrogen Bonding and Aromatic Stacking to the Affinity and Efficacy of Cannabinoid Receptor CB₂ Antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-y (SR144528). Journal of Medicinal Chemistry, 2013, 56, 6593-6612.	2.9	19
45	Physical design analysis and mainstream smoke constituent yields of the new potential reduced exposure product, Marlboro UltraSmooth. Nicotine and Tobacco Research, 2007, 9, 1197-1206.	1.4	18
46	Conformationally Constrained Analogues of N-(Piperidinyl)-5-(4-Chlorophenyl)-1-(2,4-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 Td (Dic Analysis, And Biological Evaluations. Journal of Medicinal Chemistry, 2008, 51, 3526-3539.	2.9	18
47	Truncated Orexin Peptides: Structureâ€“Activity Relationship Studies. ACS Medicinal Chemistry Letters, 2013, 4, 1224-1227.	1.3	18
48	Indenopyride derivative RTI-4587-073(I): A candidate for male contraception in stallions. Theriogenology, 2013, 80, 1006-1016.	0.9	17
49	The importance of the 6- and 7-positions of tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor. Bioorganic and Medicinal Chemistry, 2015, 23, 5709-5724.	1.4	17
50	Structure elucidation of a novel ring-constrained biaryl pyrazole CB1 cannabinoid receptor antagonist. Magnetic Resonance in Chemistry, 2003, 41, 265-268.	1.1	16
51	Novel, potent THC/anandamide (hybrid) analogs. Bioorganic and Medicinal Chemistry, 2007, 15, 7850-7864.	1.4	16
52	Diaryl urea analogues of SB-334867 as orexin-1 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2980-2985.	1.0	16
53	Comparison of cigarette, little cigar, and waterpipe tobacco smoke condensate and e-cigarette aerosol condensate in a self-administration model. Behavioural Brain Research, 2019, 372, 112061.	1.2	16
54	Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs. AAPS Journal, 2006, 8, E665-E671.	2.2	15

#	Article	IF	Citations
55	Effect of 1-Substitution on Tetrahydroisoquinolines as Selective Antagonists for the Orexin-1 Receptor. ACS Chemical Neuroscience, 2015, 6, 599-614.	1.7	14
56	The Spicy Story of Cannabimimetic Indoles. Molecules, 2021, 26, 6190.	1.7	13
57	Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-]pyrazole CB2 Ligands Using Molecular Hybridization Based on Scaffold Hopping. Open Medicinal Chemistry Journal, 2012, 6, 1-14.	0.9	12
58	Synthesis and Pharmacological Evaluation of 1-Phenyl-3-Thiophenylurea Derivatives as Cannabinoid Type-1 Receptor Allosteric Modulators. Journal of Medicinal Chemistry, 2019, 62, 9806-9823.	2.9	12
59	Assessment of structural commonality between tetrahydrocannabinol and anandamide. European Journal of Pharmacology, 2002, 435, 35-42.	1.7	11
60	Structural analogs of pyrazole and sulfonamide cannabinoids: Effects on acute food intake in mice. European Journal of Pharmacology, 2012, 695, 62-70.	1.7	11
61	Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MNâ€18. Drug Testing and Analysis, 2018, 10, 137-147.	1.6	11
62	In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. Pharmacology Biochemistry and Behavior, 2020, 193, 172918.	1.3	11
63	Analytical surveillance of emerging drugs of abuse and drug formulations. Life Sciences, 2013, 92, 512-519.	2.0	10
64	Medullary Endocannabinoids Contribute to the Differential Resting Baroreflex Sensitivity in Rats with Altered Brain Renin-Angiotensin System Expression. Frontiers in Physiology, 2016, 7, 207.	1.3	9
65	Diarylureas Containing 5-Membered Heterocycles as CB₁ Receptor Allosteric Modulators: Design, Synthesis, and Pharmacological Evaluation. ACS Chemical Neuroscience, 2019, 10, 518-527.	1.7	8
66	Modification of phencyclidine intoxification and biodisposition by charcoal and other treatments. Pharmacology Biochemistry and Behavior, 1988, 30, 371-377.	1.3	6
67	Interactions of Cannabinoids With Biochemical Substrates. Substance Abuse: Research and Treatment, 2017, 11, 117822181771141.	0.5	6
68	Complete1H and13C assignments of fluorinated analogs of dehydroepiandrosterone. Magnetic Resonance in Chemistry, 2006, 44, 1051-1053.	1.1	5
69	Neuroanatomical basis for therapeutic applications of cannabinoid receptor 1 antagonists. Drug Development Research, 2009, 70, 527-554.	1.4	5
70	Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes. Chemico-Biological Interactions, 2010, 183, 317-326.	1.7	5
71	Identification of [¹⁴C]Fluasterone Metabolites in Urine and Feces Collected from Dogs after Subcutaneous and Oral Administration of [¹⁴C]Fluasterone. Drug Metabolism and Disposition, 2009, 37, 1089-1097.	1.7	3
72	Cannabinoid CB1 receptor antagonists. Drug Development Research, 2009, 70, 525-526.	1.4	1

#	Article	IF	Citations
73	Structureâ€“Activity Relationships and Conformational Freedom of CB1 Receptor Antagonists and Inverse Agonists. , 2009, , 95-119.		1
74	Determination of l-Î±-acetylmethadol, l-Î±-noracetylmethadol and l-Î±-dinoracetylmethadol in plasma by gas chromatographyâ€”mass spectrometry. Biomedical Applications, 1994, 655, 201-211.	1.7	0
75	Conformational Characteristics of the Interaction of SR141716A with the CB1 Cannabinoid Receptor as Determined Through the Use of Conformationally Constrained Analogs. , 2008, , 707-718.		0